

Understanding the major long-term benefits of HRT

All-cause mortality

Women aged 50–59

7 deaths per 1000 women aged 50-59 each year in the UK¹



2 fewer deaths in women who initiate oral oestrogen and a synthetic progestogen within 10 years of the menopause²



2.5 fewer deaths in women who initiate body-identical oestradiol (oral or transdermal) and a progestogen within 10 years of the menopause^{3*}



Women aged 60–69

16.5 deaths per 1000 women aged 60-69 each year in the UK¹



No reduction in all-cause mortality is seen when older women start oral oestrogen and a synthetic progestogen more than 10 years after menopause²



6.5 fewer deaths in older women who start body-identical oestrogen (oral or transdermal) with a progestogen more than 10 years after menopause^{3*}



*Very few studies have assessed all-cause mortality in women using transdermal oestrogen. To our knowledge, this is the only study that has stratified all-cause mortality in women using transdermal oestrogen by age. No studies, including this one, have evaluated all-cause mortality in women using transdermal oestrogen with body-identical progesterone, which has greater cardiovascular benefits. Randomised clinical trials are needed to quantify the effects of body-identical hormones on all-cause mortality in women.

Coronary heart disease (CHD)

Women aged 50–59

9 cases of CHD per 1000 women aged 50-59 over 5 years⁴



4 fewer cases of CHD (cardiovascular death or non-fatal MI) in women who start HRT within 10 years of the menopause²



Transdermal oestradiol and body-identical progesterone have a superior cardiovascular safety profile and may further reduce cardiovascular mortality in women aged 50-59⁵

Statins don't prevent CHD or reduce mortality in women when used for primary prevention⁶

Coronary heart disease (CHD)

Women aged 60–69

18 cases per 1000 women aged 60-69 over 5 years⁴



No change in CHD incidence in women who start HRT more than 10 years after the menopause²



9 fewer deaths in women who start body-identical oestrogen (oestradiol) +/- a progestogen more than 10 years after menopause^{3*}



*Very few studies have assessed CHD risk in women using transdermal oestrogen. To our knowledge, this is the only study that has stratified CHD risk in women using transdermal oestrogen by age. No studies, including this one, have evaluated CHD risk in women using transdermal oestrogen with body-identical progesterone, which has greater cardiovascular benefits. Randomised clinical trials are needed to quantify the effects of body-identical hormones on CHD risk in women.

Statins don't prevent CHD or reduce mortality in women when used for primary prevention⁶. Some older women may benefit if they have subclinical disease - ie early signs of cardiovascular disease in their arteries, but are not yet experiencing symptoms (secondary prevention).

Diabetes

8 cases per 1000 women aged 50-79 per year⁷



2.5 fewer cases in women who take HRT⁸



Up to 5.5 fewer cases in women who start HRT using body-identical oestrogen with a synthetic progestogen within 10 years of the menopause⁹



HRT also has beneficial effects on glycaemic control in women with established diabetes (reduced insulin resistance, reduced HbA1c)¹⁰

Osteoporosis

Women aged 50–59

There are 15 fractures per 1000 women aged 50-59 each year⁷



7 fewer fractures in women aged 50-59 who use HRT¹¹



Women aged 60–69

There are 21 fractures per 1000 women aged 60-69 each year⁷



5 fewer fractures in women aged 60-69 who take HRT¹¹



Dementia

Alzheimer's disease is the most common cause of death in women in the UK¹². The drop in sex hormones (oestrogen and testosterone) during the menopause transition triggers changes in brain structure and function that progress to Alzheimer's disease in 1 in 5 women.

Whether HRT reduces dementia risk is unclear. Some studies have reported benefit, others have reported harm, and some have found that HRT doesn't influence the risk of developing dementia. Of note, only 1 study has assessed dementia risk in women using body identical hormones. It demonstrated a significantly lower risk of combined neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, in women using oestrogen with body-identical progesterone¹³.

Because the evidence is inconsistent, current guidelines do not recommend HRT for the prevention of dementia. However, a large clinical trial demonstrated that HRT is not associated with an increased risk of dying from dementia¹⁴, which suggests that HRT is not harmful. Benefit is likely to be underestimated because very few studies have assessed dementia risk in women who start HRT close to menopause when the benefits are known to be greater, and no studies have prospectively assessed dementia outcomes in women using transdermal oestrogen and body-identical progesterone.

The incidence of Alzheimer's Disease is predicted to triple by 2050. There is currently no effective therapeutic preventive strategy or cure. Body-identical HRT started within 10 years of the menopause is safe, has systemic-wide benefits, and may mitigate adverse neurological changes that increase dementia risk in some women. Women who are worried about their future risk of dementia, especially those with non-modifiable risk factors for dementia such as the APOE4 genotype, should discuss their concerns with their menopause specialist, who can support them to make an informed HRT treatment choice.

Document produced by Dr Sarah Glynn, GP Menopause Specialist.

Menopause symptom relief is a key benefit of HRT that is not included here. The most effective treatment for symptoms of hormone deficiency is hormone replacement. There is mounting evidence that HRT may have more benefits than are listed here. The long-term conditions listed above are those for which there is the strongest evidence of benefit. This information is based upon the **best currently available evidence**.



Newson Health

balance
The menopause support app

References

1. Age-specific death rate per 1,000 population in the United Kingdom in 2020, by gender. Available at: <https://www.statista.com/statistics/1125118/death-rate-united-kingdom-uk-by-age/> Accessed 21st November 2022.
2. Boardman HM, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, Gabriel Sanchez R, Knight B. Hormone therapy for preventing cardiovascular disease in postmenopausal women. *Cochrane Database Syst Rev*. 2015 Mar 10;(3):CD002229. doi: 10.1002/14651858.CD002229.pub4. PMID: 25754617.
3. Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. *Menopause*. 2015 Sep;22(9):976-83. doi: 10.1097/GME.0000000000000450. PMID: 25803671
4. Medicines and Healthcare Products Regulatory Agency. Table 2 Detailed summary of relative and absolute risks and benefits during current use from age of menopause and up to age 69, per 1000 women with 5 years of 10 years use of HRT. Available at: <https://assets.publishing.service.gov.uk/media/5d680384ed915d53b8ebdba7/table2.pdf> Accessed 21st November 2022.
5. Mueck AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. *Climacteric*. 2012 Apr;15 Suppl 1:11-7. doi: 10.3109/13697137.2012.669624. PMID: 22432811.
6. Hodis HN, Mack WJ. Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing. *Cancer J*. 2022 May-Jun 01;28(3):208-223. doi: 10.1097/PP0.0000000000000591. PMID: 35594469; PMCID: PMC9178928.
7. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB. Menopausal hormone therapy and health outcomes during the intervention and extended post stopping phases of the Women's Health Initiative randomized trials. *JAMA*. 2013 Oct 2;310(13):1353-68. doi: 10.1001/jama.2013.278040. PMID: 24084921; PMCID: PMC3963523.
8. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. *Diabetes Obes Metab*. 2006 Sep;8(5):538-54. doi: 10.1111/j.1463-1326.2005.00545.x. PMID: 16918589.
9. Pentti K, Tuppurainen MT, Honkanen R, Sandini L, Kröger H, Alhava E, Saarikoski S. Hormone therapy protects from diabetes: the Kuopio osteoporosis risk factor and prevention study. *Eur J Endocrinol*. 2009 Jun;160(6):979-83. doi: 10.1530/EJE-09-0151. Epub 2009 Mar 25. PMID: 19321660.
10. Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA. Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. *Endocr Rev*. 2017 Jun 1;38(3):173-188. doi: 10.1210/er.2016-1146. PMID: 28323934; PMCID: PMC5460681
11. Zhu L, Jiang X, Sun Y, Shu W. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. *Menopause*. 2016 Apr;23(4):461-70. doi: 10.1097/GME.0000000000000519. PMID: 26529613.
12. Public Health England. Chapter 2: Major causes of death and how they have changed. 13 July 2017. Available at: <https://www.gov.uk/government/publications/health-profile-for-england/chapter-2-major-causes-of-death-and-how-they-have-changed>.
13. Kim YJ, Soto M, Branigan GL, Rodgers K, Brinton RD. Association between menopausal hormone therapy and risk of neurodegenerative diseases: Implications for precision hormone therapy. *Alzheimers Dement (N Y)*. 2021 May 13;7(1):e12174. doi: 10.1002/trc2.12174. PMID: 34027024; PMCID: PMC8118114.
14. Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. *JAMA*. 2017;318(10):927-38
15. Collaborators GBDDF. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *Lancet Public Health*. 2022;7(2):e105-e25.